Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 19/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.73 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13244822 | 0.87 | SSTR3 (0.55) | SSTR3KCNH2SSTR1SSTR4SSTR5 | |
| SCHEMBL3002454 | 0.79 | SSTR3 (0.73) | SSTR3KCNH2SSTR1SSTR4SSTR5 | |
| SCHEMBL13244670 | 0.78 | SSTR3 (0.46) | SSTR3KCNH2 | |
| SCHEMBL3008099 | 0.78 | SSTR3 (0.45) | SSTR3KCNH2SSTR1 | |
| SCHEMBL13267092 | 0.77 | SSTR3 (0.62) | SSTR3KCNH2SSTR1SSTR4SSTR5 | |
| SCHEMBL13244879 | 0.76 | KDM4E (0.49) | SSTR3KCNH2 | |
| SCHEMBL12377698 | 0.76 | SSTR3 (0.61) | SSTR3KCNH2SSTR1SSTR4SSTR5 | |
| SCHEMBL12377697 | 0.76 | SSTR3 (0.61) | SSTR3KCNH2SSTR1SSTR4SSTR5 | |
| SCHEMBL3014223 | 0.75 | SSTR3 (0.44) | SSTR3KCNH2 | |
| SCHEMBL3008991 | 0.74 | SSTR3 (0.78) | SSTR3KCNH2SSTR1SSTR4SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| WO-2009011836-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | GPR119, SSTR3, SSTR2 | SSTR3 2/4885KCNH2 618/4885SSTR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.